{"entity":{"id":"nct05316701","kind":"trial","name":"Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies","aka":[],"tldr":"A phase 3 trial of Orca-T in acute myeloid leukaemia and myelodysplastic syndromes / neoplasms, run by Orca Biosystems, Inc., active and no longer recruiting.","summary":"Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies is a phase 3 interventional study registered as NCT05316701 by Orca Biosystems, Inc., with 187 participants enrolled, started 2022-06-21 and due to reach its primary completion in 2024-07-15. Interventions recorded: Orca-T and Standard-of-Care. Results have been posted on the registry.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05316701","url":"https://clinicaltrials.gov/study/NCT05316701"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml","mds"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["orca-biosystems"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05316701","phase":"3","setting":"A Randomized Phase III Trial of Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation With Either Orca-T, a T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells, or Standard-of-Care Allogeneic Graft","sponsor":"Orca Biosystems, Inc.","enrolled":187,"outcomes":[]},"route":"/trials/nct05316701/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"}],"company":[{"id":"orca-biosystems","kind":"company","name":"Orca Biosystems","route":"/companies/orca-biosystems/"}]}}